Opus Genetics (IRD) Free Cash Flow (2010 - 2026)
Opus Genetics (IRD) posted quarterly Free Cash Flow of -$12.7 million for Q1 2026, down 41.51% year-over-year from -$21.8 million in Q1 2025, and down 29.43% quarter-over-quarter from -$9.8 million in Q4 2025.
Powered by 
Analysis
Opus Genetics (IRD) Free Cash Flow (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported Free Cash Flow for 17 consecutive years, with -$12.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 41.51% year-over-year to -$12.7 million; the TTM figure through Mar 2026 stood at -$39.0 million (down 35.11% YoY), while the FY2025 annual figure was -$35.3 million, down 37.84% from the prior year.
- Free Cash Flow retreated to -$12.7 million in Q1 2026 per IRD's latest filing, from -$9.8 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $28.8 million in Q4 2022 and bottomed at -$12.7 million in Q1 2026.
- Historically, Free Cash Flow has averaged -$3.6 million across 5 years, with a median of -$5.7 million in 2024.
- Annual changes were most pronounced in 2022 — Free Cash Flow soared 609.94% — and 2024, when it sank 837.31%.
- Opus Genetics' Free Cash Flow stood at $28.8 million in 2022, then sank by 84.2% to $4.5 million in 2023, then slumped by 263.54% to -$7.4 million in 2024, then plunged by 32.2% to -$9.8 million in 2025, then decreased by 29.43% to -$12.7 million in 2026.
- Business Quant data shows IRD's Free Cash Flow at -$12.7 million in Q1 2026, -$9.8 million in Q4 2025, and -$6.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Opus Genetics | 446.86 Mn | 358.05 Mn | - | -11.95 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -11.95 Mn |
| Mar 31, 2026 | -12.73 Mn |
| Dec 31, 2025 | -9.83 Mn |
| Sep 30, 2025 | -6.16 Mn |
| Jun 30, 2025 | -10.27 Mn |
| Mar 31, 2025 | -8.99 Mn |
| Dec 31, 2024 | -7.44 Mn |
| Sep 30, 2024 | -5.13 Mn |
| Jun 30, 2024 | -7.29 Mn |
| Mar 31, 2024 | -5.72 Mn |
| Dec 31, 2023 | 4.55 Mn |
| Sep 30, 2023 | -3.00 Mn |
| Jun 30, 2023 | 989,000.00 |
| Mar 31, 2023 | -3.65 Mn |
| Dec 31, 2022 | 28.79 Mn |
| Sep 30, 2022 | -4.50 Mn |
| Jun 30, 2022 | -3.81 Mn |
| Mar 31, 2022 | -6.17 Mn |
| Dec 31, 2021 | -5.65 Mn |
| Sep 30, 2021 | -3.58 Mn |